{
  "id": "mhgap#risk_safety_4e07bf09",
  "content": "There is no evidence on reduction in risky environmental factors that have an impact on\nbehaviours and user/family satisfaction. depression symptoms and functioning.\ny If an antidepressant is being considered for an y Adolescents receiving fluoxetine should be\nindividual, this should be done in consultation with maintained under close clinical monitoring for\nthe adolescent and their family/caregivers, given improvement in symptoms and prevention of\nfindings that some of these medicines may be adverse effects.\nassociated with increased risk of suicide and suicide y A specialist care provider should reassess the\nattempts. adolescent’s management plan at least once\ny The cost of these medicines is high, with the per year.\nexception of fluoxetine, which is also on the WHO\n45\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.4 Conditions related to stress (STR)\nSTR1. For adults with post-traumatic stress disorder (PTSD),\nare psychological interventions effective compared with\ntreatment as usual, waitlist or no treatment?\nRecommendation (update): Psychological interventions should be considered for adults with post-\ntraumatic stress disorder (PTSD). Namely, these include:\ny individual face-to-face cognitive behavioural therapy (CBT) with a\ntrauma focus;6\ny group face-to-face CBT with a trauma focus;",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "stress",
      "study",
      "relationships",
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety There is no evidence on reduction in risky environmental factors that have an impact on\nbehaviours and user/family satisfaction. depression symptoms and functioning.\ny If an antidepressant is being considered for an y Adolescents receiving fluoxetine should be\nindividual, this should be done in consultation with maintained under close clinical monitoring for\nthe adolescent and their family/caregivers, given improvement in symptoms and prevention of\nfindings that some of these medicines may be adverse effects.\nassociated with increased risk of suicide and suicide y A specialist care provider should reassess the\nattempts. adolescent’s management plan at least once\ny The cost of these medicines is high, with the per year.\nexception of fluoxetine, which is also on the WHO\n45\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n3.4 Conditions related to stress (STR)\nSTR1. For adults with post-traumatic stress disorder (PTSD),\nare psychological interventions effective compared with\ntreatment as usual, waitlist or no treatment?\nRecommendation (update): Psychological interventions should be considered for adults with post-\ntraumatic stress disorder (PTSD). Namely, these include:\ny individual face-to-face cognitive behavioural therapy (CBT) with a\ntrauma focus;6\ny group face-to-face CBT with a trauma focus; There is no evidence on reduction in risky environmental factors that have an impact on\nbehaviours and user/family satisfaction. trầm cảm symptoms and functioning."
}